APA (7th ed.) Citation

Y, T., A, T., M, O., SI, I., K, N., Y, M., . . . Y, K. (2025). Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. Investigational new drugs, 43(1), 101. https://doi.org/10.1007/s10637-024-01500-9

Chicago Style (17th ed.) Citation

Y, Taniguchi, et al. "Stage-specific Efficacy of Osimertinib in Treatment-naïve EGFR-mutant Non-small Cell Lung Cancer According to Baseline Genetic Alterations in Circulating Tumor DNA." Investigational New Drugs 43, no. 1 (2025): 101. https://doi.org/10.1007/s10637-024-01500-9.

MLA (9th ed.) Citation

Y, Taniguchi, et al. "Stage-specific Efficacy of Osimertinib in Treatment-naïve EGFR-mutant Non-small Cell Lung Cancer According to Baseline Genetic Alterations in Circulating Tumor DNA." Investigational New Drugs, vol. 43, no. 1, 2025, p. 101, https://doi.org/10.1007/s10637-024-01500-9.